Swiss Market Community
Our community narratives are driven by numbers and valuation.
Swiss Investing Ideas
Global Weekly Picks
Roche Holding will see a 4.2576% revenue growth shaking the market
Valuation ### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der Ergebnisse Roche hat für das Jahr 2024 ein solides Wachstum von 7 % auf 60,5 Mrd. CHF erzielt, was die Erwartungen leicht übertroffen hat.Read more
Biotech longerterm bet
211011 Draupnir noch ein Anteil von rund 55,5% an Polypeptide. Der «Free Float» an der Börse SIX erhöht sich dadurch gleichzeitig von 40,0 auf rund 44,5%.Read more
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.Read more
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Catalysts Preliminary Unaudited Revenue and Cash Revenue: €266.8 million, representing a year-on-year increase of 188% compared to €92.8 million in 2023. This includes significant project-based revenues from GI Genius™ and Winlevi® of €190.2 million.Read more
Electrification And Digital Transformation Will Accelerate Market Leadership
Key Takeaways Strong global demand and record order pipeline position ABB for sustained revenue growth, operational leverage, and consistent margin improvement across key markets and segments. Value creation from the Robotics spin-off and shift toward digital services and local production enhances ABB's market share potential and supports long-term profit growth.Read more
BARN: Recent Price Momentum Will Sustain Improved Confidence In Market Position
Key Takeaways Strategic investments and supply chain expansions in North America and Asia aim to enhance revenue growth and stabilize future earnings. Secured bean supply and a focus on cost efficiencies are intended to stabilize input costs and improve net margins.Read more
Expanding Facilities And Secular Trends Will Fuel Peptide Therapeutics Demand
Key Takeaways Rapid facility ramp-ups and integrated process innovations could drive substantial, underestimated margin and efficiency gains, outpacing analyst expectations for growth and profitability. Leadership in advanced peptide and oligonucleotide manufacturing, coupled with regulatory and ESG strengths, uniquely positions Bachem to capture market share and secure recurring revenue.Read more
Reducing Wind Footprint And Investing In Niche Markets Will Strengthen Future Prospects
Key Takeaways Restructuring and resizing in wind and fiber operations focus on profitable markets, improving margins and earnings by eliminating loss-making segments. Investment in Marine and Industrial markets aims at revenue growth through specialized foams, recycled PET, and targeting high-value niche markets.Read more
Synertia And CA20 Will Expand Market Presence In The Semiconductor Industry
Key Takeaways Expansion in Malaysia and strategic advancements aim to enhance manufacturing efficiency and operational resilience, potentially boosting profitability and reducing production costs. Investment in new products and technologies like Synertia and CA20 targets high-growth semiconductor sectors, driving revenue growth and strengthening customer relationships.Read more
